PARP1 and ovarian cancer: The original approval of three different PARP inhibitors (olaparib, niraparib and rucaparib) as maintenance therapy for recurrent platinum sensitive patients with gBRCA mutations marked an important advance in the management of ovarian cancer patients47–49.